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Abstract
We have identified an alternative pathway of tumorigenesis in sporadic colon cancer, involving microsatellite instability due to
mismatched repair methylation, which may be driven by mutations in the BRAF gene (V600E). Colorectal cancer (CRC) is the
most common cancer in the world, and African Americans show a higher incidence than other populations in the United States.
We analyzed sporadic CRCs in Omani (of African origin, N = 61), Iranian (of Caucasian origin, N = 53) and African American
(N = 95) patients for microsatellite instability, expression status of mismatched repair genes (hMLH1, hMSH2) and presence of
the BRAF (V600E) mutation. In the Omani group, all tumors with BRAF mutations were located in the left side of the colon, and
for African Americans, 88% [7] of tumors with BRAF mutations were found in the right side of the colon. In African Americans,
31% of tumors displayed microsatellite instability at two or more markers (MSI-H), while this rate was 26% and 13% for tumors
in the Iranian and Omani groups, respectively. A majority of these MSI-H tumors were located in the proximal colon (right side)
in African American and Iranian subjects, whereas most were located in the distal colon (left side) in Omani subjects. Defects
in hMLH1 gene expression were found in 77% of MSI-H tumors in both African Americans and Iranians and in 38% of tumors
in Omanis. BRAF mutations were observed in all subjects: 10% of tumors in African Americans (8/82), 2% of tumors in Iranians
(1/53), and 19% of tumors in Omanis (11/59). Our findings suggest that CRC occurs at a younger age in Omani and Iranian
patients, and these groups showed a lower occurrence of MSI-H than did African American patients. Our multivariate model
suggests an important and significant role of hMLH1 expression and BRAF mutation in MSI-H CRC in these populations. The
high occurrence of MSI-H tumors in African Americans may have significant implications for treatment, since patients with MSI-
H lesions display a different response to chemotherapeutic agents such as 5-fluorouracil.
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Introduction
Colorectal cancer (CRC) is the second leading cause of
cancer-related deaths in the United States, despite recent
improvements in the diagnosis and treatment of the dis-
ease [1]. The incidence and mortality rate of CRC are
higher in African Americans than in the general popula-
tion [1,2]. Many epidemiological and genetic investiga-
tions have focused on African Americans [2-4] with the
goal of deciphering the reasons for such disparities. While
socio-economic factors are likely involved (e.g., African
Americans tend to reach more advanced stages of disease
before diagnosis), biological factors also contribute to the
disparity [5]. Dietary and environmental factors certainly
play an important role, as Japanese immigrants to the US
show higher colon cancer rates than do Japanese people
living in Japan. The latter also started showing higher rates
of colon cancer along with the westernization of their
diets [6,7].
The recent approval by the FDA of Bidil, a drug for heart
failure in African Americans, illustrates ethnical/racial
genetic specificities that lead to different interactions with
a given drug or molecule [8]. Only limited genetic and
epigenetic studies exist from Africa and other continents,
including Asia, that have populations known to be of Afri-
can descent. In Oman, some tribes have Bedouin roots
and others have Asian and/or African origins [9]. In gen-
eral, the Omani population has Asian and African ethnic-
ities [10]. Other ethnic groups in Asia are not considered
to be of African descent, such as Caucasian people in Iran.
In this study, we used samples from patients treated for
CRC in Oman, Iran and the US (African Americans) for
genetic and epigenetic investigation. We chose these three
populations based on their similarities and differences in
African ethnicity [10-14].
Colon cancer develops through different pathways, all
involving changes at the chromosomal or genetic levels.
Other modifications occur epigenetically and affect the
level of expression of certain targeted genes that are essen-
tial for the normal control of cell division within the
colon mucosa [15]. It is now widely accepted that spo-
radic colorectal cancers frequently arise from pre-neoplas-
tic lesions through the activation of oncogenes (K-ras,
BRAF) and the inactivation of tumor suppressor genes
(APC, p53, DCC) and mismatch repair (MMR) genes
(MLH1 and MSH2) [16,17]. Also, activating mutations in
BRAF, one of the RAF genes which encode kinases that are
regulated by Ras and mediate cellular responses to growth
signals, have been found to be associated with MSI-H can-
cers [18]. The DNA MMR process can be impeded by
genes that are either mutated [19] or silenced [4], leading
to the expression of non-functional proteins or to a lack of
expression, respectively. MMR pathway is primarily
responsible for colon cancer development in families with
Hereditary Non Polyposis Colon Cancer (HNPCC),
which represents about 5% of the generally inventoried
colon cancer cases [20].
In the present study, we analyzed samples from two differ-
ent populations of African descent (African American and
Omani) and a Caucasian population (Iranian) for micro-
satellite instability and BRAF mutations. We correlated
our findings with the silencing of genes involved in DNA
MMR. We evaluated and compared the demographic and
clinicopathological data in relation to molecular altera-
tions in specific genes (BRAF, DNA MMR) to improve our
understanding of colon tumorgenesis in people living in
different environments.
Methods
Patients
A total of 95 African American CRC patients (from
Howard University and Johns Hopkins Hospital between
1997 and 2004; self-identified as African American), 61
Omani CRC patients (from the two tertiary referral hospi-
tals in Oman Sultan Qaboos University Hospital and the
Royal Hospital between 2000 and 2004 who underwent
surgical resection) and 53 Iranian CRC patients (from the
two referral hospitals in Shiraz, Iran Namazi Hospital and
Saadi Hospital) were included in this study. Formalin-
fixed, paraffin-embedded archival tissue was collected
(with approval from all above sites' Institutional Review
Boards) and clinical data was obtained (including race,
age, site of primary tumor, mucin production and tumor
differentiation). In addition, the family history of cancer
was analyzed to identify those pedigrees that met either
the Amsterdam I or Amsterdam II criteria for HNPCC. The
study was performed on unselected and serially collected
specimens. All cases underwent surgery within the given
collection.
DNA isolation and MSI analysis
Archived and fresh tumor blocks were cut into 5-μm sec-
tions on Superfrost slides (Fisher Scientific, Pittsburgh,
PA). The tumor and normal area were diagnosed by a
pathologist using the H&E matched slide and microdis-
sected to pinpoint the tumor areas as well as normal areas
from at least two slides. A pinpoint DNA extraction kit
was used as recommended by the manufacturers (Zymo
Research). The extracted tumor and normal matched DNA
were used as template in PCR reactions where five micro-
satellite markers (Cancer Research 58:5248–5257,
1998;[21]; BAT25, BAT26, D17S250, D5S346 and
D2S123) were used to evaluate MSI status. PCR products
were analyzed in a 3130 ABI GeneScan. Those displaying
DNA instability at only one of the markers (including the
dinucleotides) were labeled MSI-L, those displaying insta-
bility with two or more markers were labeled MSI-H, and
those displaying no instability with any of the five mark-Molecular Cancer 2008, 7:68 http://www.molecular-cancer.com/content/7/1/68
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ers tested were labeled MSS. Due to unclear characteristics
of MSI-L, we combined MSS and MSI-L as one group
(non-MSI-H).
Methylation-specific PCR
The presence or absence of hMLH1 and p16 methylation
in cancers was determined by comparing the signals from
tumor-derived tissues with those from normal, non-can-
cerous tissues, as previously described [3,4]. DNA was
extracted from the samples using a Gentra DNA extraction
kit (Gentra) and was modified using DNA modification
kits as recommended by the manufacturers (Zymo
Research). MSP was used to distinguish unmethylated
from methylated alleles, based on sequence alterations
produced by bisulfite treatment of DNA, to convert
unmethylated cytosines to uracil. These changes are iden-
tified by subsequent PCR using primers specific to the
methylated (unchanged) or unmethylated (changed)
DNA. Briefly, 1 μg of genomic DNA was denatured by
treatment with NaOH and was modified by the addition
of sodium bisulfite. DNA samples were purified using
Wizard DNA purification resin according to the manufac-
turer's instructions (Promega). These DNA samples were
again treated with NaOH, then precipitated with ethanol
and resuspended in water. PCR reactions were performed
using the primer pairs described below in the following
reaction mix: 10× PCR buffer [16.6 mM ammonium sul-
fate, 67 mM Tris (pH 8.8), 6.7 mM MgCl2, and 10 mM 2-
mercaptoethanol], dNTPs (each at 1.25 mM), primers (50
pmol each per reaction), and bisulfite-modified DNA (50
ng) in a final volume of 50 μl. Reactions were hot-started
at 95°C for 5 min, after which 1.25 units of Taq polymer-
ase (Life Technologies, Inc.) were added. Amplification
was carried out in an Applied Biosystem temperature
cycler for 40 cycles (30 sec at 95°C, 30 sec at 59°C then
30 sec at 72°C), followed by a final 4-min extension at
72°C. Two sets of primers were used simultaneously to
check for methylated or unmethylated CpG islands at the
level of hMLH1 and p16 promoters. The primer sequences
were as in our previous study [4]. Controls for methylated
and unmethylated DNA were DNA from the SW48 colon
cancer cell line and normal lymphocytes, respectively.
Each PCR reaction product (10 μl) was directly loaded
into a 2% agarose gel, which was later stained with ethid-
ium bromide to allow DNA visualization under UV illu-
mination. The presence of a band in unmethylated tumor
and matched normal with the absence of a methylation
band in the tumor was defined as unmethylated. How-
ever, when a methylated band was present for tumor and
absent for the normal, we defined the sample as methyl-
ated (or semi-methylated if both unmethylated or meth-
ylated bands were present in the tumor).
Histopathological analysis
Independent pathologists who were unaware of the MSI
status of any of the samples evaluated specific histopatho-
logical characteristics. Grading of tumors was achieved by
staining with Hematoxylin-Eosin (H&E). Tumors were
classified as proximal (proximal to the splenic flexure) or
distal. The TNM system of the International Union against
cancer was used for tumor staging. Mucin production was
evaluated using the modified criteria of Wiggers et al, [22]
and reported as absent (no extracellular mucin produc-
tion), focal (when extracellular mucin production was
present in < 50% of the cells) or predominant (when the
area of extra cellular mucin production was present in ≥
50% of the cells).
Immunohistochemistry
Tissue obtained from paraffin-embedded blocks was used
for the immunohistochemistry experiments. Sections (5
μm) were mounted on charged glass slides, deparaffinized
with xylene for 2 × 10 min and rehydrated using a graded
ethanol series. Antigen retrieval was performed by placing
the samples in a microwave oven for 12 min, with occa-
sional interruption to avoid tissue degradation by exces-
sive heat. The slides were then treated with hydrogen
peroxide, followed by incubation with the primary and
secondary antibodies, a streptavidin-biotin complex, an
amplification reagent, streptavidin-peroxidase and sub-
strate-chromogen solution using the Envision system
according to the manufacturers' protocol (DAKO). The
samples were then counterstained with hematoxylin,
rinsed with ethanol, dried and visualized by a light micro-
scopy. Tissue samples to which no primary antibody had
been added were used as negative controls. All immuno-
histochemistry reagents were purchased from DAKO
(Carpinteria, CA) and the antibodies (hMLH1 clone
G168-15, 1/100 dilution and hMSH2 clone 556349, 1/
500 dilution) were purchased from PharMigen (San
Diego, CA). The slides were read by pathologists unaware
of the MSI status. Absence of MLH1 and MSH2 nuclear
expression was defined as negative staining.
BRAF mutation analysis
Samples were analyzed for the presence of a point muta-
tion that frequently takes place in the oncogene BRAF,
leading to the change of valine into glutamic acid at posi-
tion 600 of the BRAF protein. DNA from the analyzed
samples was used as a template in PCR reactions using
two BRAF primers encompassing BRAF exon 15 where the
above substitution is known to take place. Amplified frag-
ments were analyzed by sequencing in a 3130 ABI GeneS-
can to confirm the presence of the mutation.
Statistical analysis
The MSI phenotypes were divided into two groups: non-
MSI (MSS+MSI-L) and MSI-H (two or more markers
unstable). Age of patients was a continuous variable,
while the stage of the cancer, gender, location, mucin pro-
duction, differentiation, and hMLH1 and hMSH2 methyl-
ation were categorical variables. For statistical analysis,Molecular Cancer 2008, 7:68 http://www.molecular-cancer.com/content/7/1/68
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mucin production was categorized as 0 (no production),
< 50% or ≥ 50%. The distributions of categorical variables
were shown by frequency table, and for age by computing
mean (SD). We tested the distribution of categorical vari-
ables between MSI-H and non MSI-H groups by asymp-
totic Chi-Square or the Fisher's-Exact test, as appropriate
and computing of OR (95% CI). The age difference
between two groups was tested by student t test. The uni-
variate analysis was done for both races separately. We
selected race, age (as a continuous variable), differentia-
tion, tumor site (right vs. left), stage [1-4], BRAF mutation,
hMHL1 and hMSH2 expression (positive vs. negative),
and P16 and hMHL1 methylation to enter to a Backward
logistic regression model, with MSI as a dependent varia-
ble. Univariate analysis showed evidences of interaction
between race and some markers, so we developed a
model, with interaction terms. Then a final model was
developed with the variables with significant effect (p <
0.05) on the risk of MSI-H including interaction term. All
analysis was performed by the SPSS program 15.0 (Chi-
cago, IL).
Results
Distinct clinicopathological features according to MSI 
status and tumor Site
The clinical and pathological characteristics of the
patients are presented in Table 1, 2, 3. For MSI experi-
ments, we analyzed samples from 95 African American
patients, (56 females, 39 males). The mean (SD) age of
the African American patients (at the time of tissue collec-
tion) was 65.7 [15] years. Of the 95 analyzed African
American samples, 29 (30.5%) were MSI-H, and 66
Table 1: Clinicopathological and genetic characteristics of AA CRC cases
African Americans
All non-MSI-H MSI-H Odds Ratio (95% CI) P
Number of patients 95 66 (69)a 29 (31)a
Mean Age 65.7+15.0
-
65.2+14.0
-
65.9+17.5
-
0.84
Gender 0.39
Female 56 (59) 37 (57) 19 (66) 1
Male 39 (41) 29 (43) 10 (34) 0.67(0.27–1.67)
Site 0.47
Distal 38 (40) 28 (43) 10 (34) 1
Proximal 57 (60) 38 (57) 19 (66) 0.71(0.29–1.77)
Mucin Production 95 0.15
None 68 (72) 51(77) 17(58) 1
< 50% 15 (15) 9 (14) 6 (21) 2.0(0.62–6.44)
> 50% 12 (13) 6 (9) 6(21) 3.0(0.85–10.55)
Differentiation 90 0.47
Well 3 (3) 2 (3) 1 (3) 1
Moderate 71 (79) 51 (83) 20 (72) 0.64(0.5–8.62)
Poor 16 (18) 9 (14) 7 (25) 0.5(0.17–1.54)
Stage 92 0.59
Stage 1 8 (9) 7 (11) 1 (3) 1
Stage 2 37 (40) 24 (38) 13 (45) 0.67(0.09–4.93)
Stage 3 35 (38) 23 (37) 12 (41) 1.08(0.27–4.29)
Stage 4 12 (13) 9 (14) 3 (11) 0.8(0.2–3.27)
BRAF 82 0.00
wild type 74 (90) 59 (98) 15 (68)
V600E 8 (10) 1 (2) 7 (32) 27.5(3.1–241.3)
hMLH1 methylation (MSP) 70 0.33
Unmethylation 4 (6) 2 (4) 2 (10) 1
Methylation 66 (94) 48 (96) 18 (90) 0.38(0.5–2.87)
p16 methylation (MSP) 47 0.37
Unmethylation 28 (60) 14 (54) 14 (67) 1
Methylation 19 (40) 12 (46) 7 (33) 0.58(0.18–1.92)
hMLH1 expression by IHC 76 0.00
Normal 50 (65) 45 (83) 5 (23) 1
Negative 26 (35) 9 (17) 17 (77) 16.67(5–50)
hMSH2 expression by IHC 74 0.29
Normal 66 (89) 46 (87) 20 (95) 1
Negative 8 (11) 7 (13) 1 (5) 0.33(0.04–2.86)Molecular Cancer 2008, 7:68 http://www.molecular-cancer.com/content/7/1/68
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(69.5%) were non-MSI-H (Table 1). Four MSI-H patients
had a strong family history of colon cancer, and met the
Amsterdam criteria for HNPCC. Thirteen other patients
met the Bethesda criteria [23], based on the age at diagno-
sis of CRC; however, tissue samples from thirteen of these
patients were non-MSI-H. Sixty-one tissue samples from
the Omani patients were analyzed (24 females, 37 males;
mean age (SD) was 52.7 (13.6). MSI analysis showed that
53 (86.9%) of Omani samples were non-MSI-H, and 8
(13.1%) were MSI-H (Table 2). From this group, five
patients that were MSI-H had a strong family history of
colon cancer meeting the Amsterdam criteria for HNPCC.
Nineteen other patients met the Bethesda criteria [23],
based on the age at diagnosis of CRC; however, tissue
samples from fourteen of these patients were non-MSI-H.
Fifty-three tissue samples from Iranian patients were ana-
lyzed (64% female; mean age (SD) in Iranian patients was
59.8 (12.7; Table 3). Fourteen (26%) of the Iranian sam-
ples were MSI-H tumors. The HNPCC and Familial Ade-
noma Polyposis were not seen in Iranian patients in this
study. In the Omani and Iranian populations, there were
more MSI-H tumors in males than females (75% vs 25%
in Omani; 57% vs. 43% in Iranian); in the African Amer-
ican group, there were more MSI-H tumors in females
(66% vs 34%). However, these gender differences were
insignificant trends.
A total of 57 (60%) primary African American tumors
were located in the proximal colon and 40% [38] were
distal. Within the MSI-H group, 19 (66%) were proximal
Table 2: Clinicopathological and genetic characteristics of Iranian CRC cases.
Iranian
All non-MSI-H MSI-H Odds Ratio P
Number of patients 53 39 (74)a 14 (26)a
Mean Age 59.8+12.7
-
59.9+12.7
-
59.4+13.1
-
0.90
Gender 53 0.52
Female 19(36) 13(33) 6(43) 1
Male 34(64) 26(67) 8(57) 0.67(0.19–2.33)
Site 53 0.00
Distal 40(76) 37(95) 3(21) 1
Proximal 13(24) 2(5) 11(79) 66.67(10–500.00)
Mucin Production NA
None NA
< 50% NA
> 50% NA
Differentiation 53 0.00
Well 29(54) 26(67) 3(22) 1
Moderate 22(42) 13(33) 9(64) 6(1.38–26.00)
Poor 2(4) 0 2(14) NA
Stage 53 0.67
Stage 1 000 N A
Stage 2 12(23) 10(26) 2(14) 1
Stage 3 37(70) 26(67) 11(79) 0.60(0.04–9.16)
Stage 4 4(7) 3(7) 1(7) 1.27(0.12–13.58)
BRAF 53 0.09
Wild type 52(98) 39(100) 13(93)
V600E 1(2) 0 1(7) NA
hMLH1 methylation (MSP) 53 0.00
Unmethylation 42(79) 38(97) 4(29) 1
Methylation 11(21) 1(3) 10(71) 95.00(9.53–946.94)
p16 methylation (MSP) 53 0.00
Unmethylation 45(85) 38(97) 7(50) 1
Methylation 8(15) 1(3) 7(50) 38.00(4.03–358.74)
hMLH1 expression by IHC 25 0.00
Normal 15(60) 12(100) 3(23)
Negative 10(40) 0 10(77) NA
hMSH2 expression by IHC 25 1.00
Normal 24(96) 12(100) 12(92)
Negative 1(4) 0 1(8) NAMolecular Cancer 2008, 7:68 http://www.molecular-cancer.com/content/7/1/68
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and 10 (34%) were distal (Table 1). The non-MSI-H group
showed a distribution with 38 (57%) proximal tumors
and 28 (43%) distal tumors. Mucin production was noted
in 27 tumors including 12 MSI-H and 15 non-MSI-H
tumors. Fifty-one of the Omani tumors were located in
the distal colon (84%). The prevalence of distal lesions in
the MSI-H group was 87%. Of the 61 Omani samples, 47
(77%) showed no mucin production, 14 (23%) had focal
mucin production (Table 2). The percentage of lesions
that produced mucin was 20% and 37% for MSI-H and
Non-MSI-H, respectively. Frequency of proximal tumors
in Iranian patients was 13 (24%) and the prevalence of
proximal lesions in the MSI-H group was 79% [11]. In
univariate analysis, a proximal location increases the rate
of MSI-H in Iranian patients significantly (OR =
66.67(10–500)) (p = 0.001; Table 3)).
The majority of tumors were found to be moderately dif-
ferentiated in African Americans (79%) and Omanis
(82%; Table 1, 2). Iranian tumors were mostly well differ-
entiated (54%). The percentage of moderately differenti-
ated tumors was 86% in the MSI-H Omani group
compared with 72% in African Americans and 64% in Ira-
nians (Table 1, 3). In addition, seven and one MSI-H
tumors showed poor differentiation in African Americans
and Omanis, respectively. While in African Americans,
one MSI-H was well differentiated, no patient in Iranian
non-MSI-H cases was poorly differentiated (Table 1, 3).
The difference was insignificant trend in African Ameri-
cans and Omanis but in Iranian patients differentiation
was significantly correlated with MSI-H occurrence. This
finding was not sustained in multivariate analysis.
Table 3: Clinicopathological and genetic characteristics of Omani CRC cases.
Omani
All non-MSI-H MSI-H Odds Ratio P
Number of patients 61 53 (87)a 8 (13)a
Mean Age 52.7+13.6
-
53.1+12.8
-
51.5+19.2
-
0.76
Gender 0.37
Female 24 (39) 22 (42) 2 (25) 1
Male 37 (61) 31(58) 6 (75) 2.12(0.39–11.55)
Site 61 0.75
Distal 51 (84) 44(83) 7(87) 1
Proximal 10 (16) 9(17) 1(13) 1.43(0.16–13.11)
Mucin Production 61 0.44
None 47 (77) 42(78) 5 (63) 1
< 50% 14(23) 11 (20) 3(37) 2.3(0.47–11.10)
> 50% 000 N A
Differentiation 60 0.44
Well 7 (12) 7 (14) 0 NA
Moderate 49(82) 43 (81) 6(86) 1
Poor 4 (6) 3 (6) 1 (14) 2.39(0.21–26.84)
Stage 61 0.28
Stage 1 1 (2) 1 (2) 0 NA
Stage 2 20 (33) 15 (28) 5 (62) 1
Stage 3 31 (50) 29 (55) 2 (25) 0.21(0.02–1.50)
Stage 4 9 (15) 8 (15) 1 (13) 0.38(0.01–4.41)
BRAF 59 0.62
Wild type 48 (81) 42 (82) 6 (75) 1
V600E 11 (19) 9 (18) 2 (25) 1.56(0.27–9.0)
hMLH1 methylation (MSP) 49 0.47
Unmethylation 8 (16) 6(14.6) 2 (25) 1
Methylation 41 (84) 35 (85.4) 6 (75) 0.51(0.08–3.17)
p16 methylation (MSP) 44 0.09
Unmethylation 27(62) 20 (56) 7 (88) 1
Methylation 17 (38) 16 (44) 1 (12) 0.18(0.02–1.61)
hMLH1 expression by IHC 61 0.68
Normal 42 (69) 37(70) 5 (62) 1
Negative 19 (32) 16 (30) 3(38) 1.39(0.29–6.67)
hMSH2 expression by IHC 61 0.63
Normal 56 (92) 49 (92) 7(87) 1
Negative 5 (8) 4 (8) 1(13) 1.75(0.17–16.67)
Parentheses indicate percentages: All values are based on column except a based on row. MSP = methylation-specific PCR; IHC = 
immunohistochemistryMolecular Cancer 2008, 7:68 http://www.molecular-cancer.com/content/7/1/68
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Most of the patients in the series were stage II or higher
(Table 1, 2, 3), with 45% [13] of African American, 62%
[5] of Omani, and 14% [2] of Iranian MSI-H lesions at
stage II. Thirty-eight percent [24] of African American,
28% [15] of Omani, and 23% [12] of Iranian of the non-
MSI-H lesions were at stage II (Table 3). Forty-one percent
[12] of African American, 25% [2] of Omani, and 79%
[11] of Iranian of the MSI-H lesions were at stage III
(Table 1, 2, 3). Thirty-seven percent [23] of African Amer-
ican, 55% [29] of Omani, and 67% [26] of Iranian of the
non-MSI-H lesions were at stage III. Fourteen percent [9]
of African American, 15% [8] of Omani, and 7% [3] of Ira-
nian of the non-MSI-H lesions were at stage IV (Table 1, 2,
3). There was insignificant trend in the stage of the lesions
between the MSI and non-MSI-H groups.
Correlation between methylation pattern of the hMLH1 
promoter and MSI status
Among MSI-H samples, hMLH1 promoter methylation
was found in 90% [18] of African American, 75% [6] of
Omani and 71% [10] of Iranian tumors, confirming a pre-
vious finding of predominant methylation of these genes
of the promoter in Africans (Table 1, 2, 3) [3,4]. Non-MSI-
H tumors in both African Americans and Omani tumors
showed methylation of the hMLH1 promoter as well (>
80%). In Iranian non-MSI-H patients, the frequency of
hMLH1 methylation was 3% [1]. The methylation status
of hMLH1 does not seem to be gender- or stage-specific.
In multivariate analysis, including the interaction terms,
the hMLH1 methylation has a significant effect on MSI-H
occurrence (OR = 13.84(1.05–182.72); p = 0.046) (Table
4). In MSI-H tumors, p16 methylation occurred in 33%
[7] of African American, 12% [1] of Omani and 50% [7]
of Iranian tumors. While it was more than 40% in non-
MSI-H tumors in African Americans and Omani patient
populations, this figure was 3% [1] in Iranian non-MSI-H
CRC patients.
Correlation between hMLH1 protein expression and MSI 
status
Expression of the hMLH1 and hMSH2 nuclear proteins
was examined immunohistochemically in paraffin-
embedded tissue sections [4]. In all cases, non-neoplastic
cells displayed positive nuclear staining for both hMLH1
and hMSH2. The nuclear stained slides were read by two
different pathologists, and normal tissue on slides where
no primary antibody stained was used as negative control.
In total, 76 African American, 61 Omani, and 25 Iranian
cases were analyzed. Thirty-five and 11% of African Amer-
ican tumors assayed showed loss of staining for hMLH1
and hMSH2, respectively. Moreover, loss of hMLH1 and
hMSH2 staining was observed in 77% and 5% of MSI-H
African American tumors, respectively (Table 1). The loss
of hMLH1 and hMSH2 staining was observed in 17% and
13% of non-MSI-H African American tumors, respectively
(Table 1). In Omani tumors: 38% (n = 3) of the MSI-H
tumors showed absences of hMLH1 expression (Table 2);
30% (n = 16) of the non-MSI-H tumors had negative
hMLH1. Fifty-six cases of Omani patient tested for the
presence of hMSH2 protein by immunohistochemical
staining, seven Omani cases were MSI-H. In Iranian
patients, 77% [10] of the MSI-H tumors were negative for
hMLH1 expression (Table 3); all of non-MSI-H tumors
were positive for hMLH1 expression, while for hMSH2
these figures were 8% [1] and 0, respectively. In multivar-
iate analysis, including the interaction terms, the hMLH1
expression has a significant preventive effect on MSI-H
occurrence (OR = 0.13(0.04–0.41); p < 0.0001; (Table
4)).
Correlation between BRAF mutation and MSI status
Samples were analyzed for the presence of a point muta-
tion that frequently occurs in the oncogene BRAF leading
to the change of valine to glutamic acid at position 600 of
the BRAF protein. In all samples only 10% [8] African
American, 19% [11] Omani and 2% [1] Iranian samples
displayed the mutation by sequencing (Table 1, 2, 3). In
the MSI-H group, the BRAF mutation was 32% [7] in Afri-
can Americans, 25% [2] in Omani, and 7% [1] in Iranian,
respectively. Eighteen percent and 2% of non-MSI-H
tumors carry the BRAF mutation in African Americans and
Omanis, respectively, while none of the Iranians carried a
BRAF mutation in this group. A BRAF mutation is a signif-
icant risk factor for MSI-H occurrence even after control-
ling for other factors in the multivariate model (OR =
12.11(2.82–52.03); p = 0.001; (Table 4)).
Discussion
DNA MMR gene silencing and/or mutation are the main
factors leading to accumulation of mutations within genes
and general genome instability [19]. The MSI phenotype
resulting from such alterations is one of the early events
leading to the development of certain cancers. It occurs in
Table 4: Multivariate analysis for the risk factors associated with 
MSI-H occurrence (Model including single term and interactions 
effect)
Factor OR (95% CI) P value
Normal hMLH1 expression by IHC 0.13(0.04–0.41) < 0.0001
BRAF V600E mutation 12.11(2.82–52.03) 0.001
hMLH1 methylation 13.84(1.05–182.72) 0.046
Race 0.946
African-Americans 1
Omani 0.83(0.04–0.18.30) 0.905
Iranian 0.68(0.07–6.58) 0.739
hMLH1 methylation* Race 0.072
hMLH1 methylation* Omani 0.04(0.01–1.74) 0.091
hMLH1 methylation* Iranian 0.02(0.01–0.63) 0.032
* indicates the interaction term between two variables.Molecular Cancer 2008, 7:68 http://www.molecular-cancer.com/content/7/1/68
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patients with Lynch syndrome and in those that acquire
such alterations somatically [24]. Another event occurring
in adenoma polyp is mutation in oncogenes, specifically
in K-ras and BRAF genes in the case of colon cancer [24-
26]. The linkage between BRAF mutations and MSI was
previously reported [27-30]. In general, Omani people
have a mixed Asian and African ethnic background [10]
and Iranians are of Caucasian ethnicity. Here we demon-
strate that in African Americans, Omanis and Iranians, the
MSI phenotype occurs in 31%, 26% and 13% of CRC
tumors, respectively. In addition, the locations of the
tumors in African Americans and Iranians were primarily
proximal compared to distal for Omanis; and BRAF muta-
tions were more prevalent in Omanis than African Amer-
icans or Iranians (19%, 10% and 2%, respectively). While
the MSI phenotype in this sample of African Americans is
less than we previously reported (43–45%), [3,4] it
appears to be more prevalent in African Americans than in
others and still high in the general US population [31-33].
The current sample contained more African Americans
and more right-sided than left-sided tumors. The MSI phe-
notype was more common in proximal tumors than in
distal ones (p = 0.47), strengthening earlier findings of
such an association [31-33]. The prevalence of MSI-H
tumors indicates the importance of BRAF mutations, par-
ticularly in the African Americans, since they represent a
higher mutation profile than Iranians and Omanis. This
finding suggests that, at least within the MSI-H group of
patients, the BRAF V600E mutation in exon 15 is the
major event leading to tumor development. In addition,
the distal location of Omani MSI-H tumors may also play
an important role in the presentation of the disease com-
pared to proximal ones in the African American and Ira-
nian populations. The lower frequency of MSI-H tumors
observed in Omani patients could be related to the higher
frequency of the distal location. This needs to be verified
in a larger sample size.
The absence of hMLH1 expression was more pronounced
in MSI-H tumors from African American and Iranian
patients (77% of tumors in these groups showed no
hMLH1 expression). However, for Omanis, the moderate
hMLH1expression (62%) in MSI-H may indicate some
other defects in the component of base excision repair
(Oxidative DNA damaged markers such as 8-hydroxygua-
nosine), or distinct lymphangiogenic phenotype associ-
ated with MSI other than in mismatch repair genes. The
tumors that we have studied included MSI-H tumors that
were negative using immunohistochemistry for hMLH1.
This incidence is less than compared to that described in
the literature (77% [34]), although the numbers
described are small.
These results are in concordance with the MSP analysis
showing that a majority of samples displayed methylation
at the hMLH1 promoter. The methylation of hMLH1 is
most likely from a specific genome methylation process in
progression of colon cancer. The African American group
was older than both the Omani and Iranian group. It has
been demonstrated that older people, particularly those in
the 7th–9th decade of life, have a much higher chance of
hypermethylation of hMLH1 and MSI. This is consistent
with hMLH1 methylation in the African American cancers
both in MSI-H and non-MSI cases. However, in Iranians,
a higher profile of epigenetic silencing of hMLH1 may
explain the MSI-H tumors but not in non-MSI. In addi-
tion, the distal location of Omani tumors may also play
an important role in the presentation of the disease com-
pared to the African American who has generally proximal
CRC.
Our results demonstrate that methylation of hMLH1 is
the major cause of MSI in sporadic CRC consistent with
our previous findings [3,4]. The fact that the hMLH1 gene
is methylated indicates that it may be inactivated by an
epigenetic mechanism. The association of higher levels of
CpG island methylation with more advanced histological
changes suggests that CpG methylation plays a role in
CRC [30]. However, the pathophysiology of hyper-meth-
ylation (the why, when and where) has yet to be eluci-
dated. Cancers can be classified according to their degree
of methylation. Those with high degrees of methylation
(the CpG island methylator phenotype, or CIMP) repre-
sent a clinically and etiologically distinct group that is
characterized by 'epigenetic instability'. The MSI-H and
CIMP phenotype may explain the criteria in proximal
tumors in African American and Iranian but not the distal
ones in Omani tumors; however, the CpG island methyl-
ation status of a broader panel of genes needs to be inves-
tigated to determine whether this is the case. Some
samples for MLH1 methylation failed to display MLH1
protein by immunohistochemistry and were non-MSI
(MSS and MSI-L). Possible explanations might be that the
targeted CpG island for methylation in this study is
located upstream of the gene, and has a minor effect on
the transcription of MLH1 protein [35] or that the
detected methylation is only in a small cell population
that does not reflect the overall tumor phenotype. Full
methylation of the hMLH1 promoter region and subse-
quent gene inactivation may play a crucial role in carcino-
genesis of MSI-H CRCs. Therefore, in our on-going
investigation, we are studying the methylation status of
the lesions by examining all CpG sites [36] especially
within non-MSI tumors where data reveals lack of protein
expression. Some non-MSI tumors were methylated at the
MLH1 site and this may be due to the partial or hemi-
methylation at an altered MLH1 site. This is consistent
with the lack of correlation of between the methylation
status and level of expression of MLH1[37]. Indeed, more
markers need to be considered to measure methylation inMolecular Cancer 2008, 7:68 http://www.molecular-cancer.com/content/7/1/68
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order to establish a methylation phenotype that correlates
the protein expression status and allows for the under-
standing of preferential carcinogenic pathways. Positive
staining was confirmed in adjacent normal tissue within
the same slide validating of the staining for specimens
that were found to be negative for either MLH1 or MSH2.
In addition, preferential microsatellite loci containing
large repeat units, but not loci containing mono- or dinu-
cleotide repeats units, may contribute to the non-MSI
tumors, particularly MSI-L CRC tumors.
Many explanations could account for the differences
between African Americans and the other populations.
The difference in MSI frequency might be due to genetic
specificities or to behavioral/dietary causes [38]. Dietary
factors such as folate, vitamins, and methionine may be
associated with colon cancer because of involvement in
DNA methylation and hence on the CpG island, MSI and
BRAF. A recent study questioned the unique role for die-
tary folate, alcohol, vitamins B6 and B12 and methionine
in the CIMP phenotype [39]. In addition, use of alcohol
and obesity were associated with an increased risk of
tumors that were MSI-H and CIMP-low (less than two
markers methylated) [39]. The number of lymph nodes,
distance organ metastases and additional impairment of
the MMR system may associate with the more aggressive
behavior of CRC in African Americans.
Studies have investigated the traditional (nonserrated)
adenoma-carcinoma sequence and the serrated polyp
neoplasia for BRAF and MSI. MSI-H was identified only in
the adenocarcinoma component of serrated carcinomas
[40,41]. BRAF mutation has been shown to be a specific
marker for a serrated polyp pathway that has its origin in
a hyperplastic polyp and a potential end point as MSI car-
cinoma. A recent study indicated that MSI-H in the spo-
radic colorectal cancers may be part of a clinically distinct
subgroup with a high incidence of BRAF mutation devel-
oped from serrated polyps [26]. In this study we catego-
rized the histological status of the end point such as
carcinomas with residual adenoma, the serrated polyp
neoplasia pathway and the traditional (nonserrated) ade-
noma-carcinoma sequence. However, we did not find any
evidence of serrated or serrated hyperplastic tissue in the
MSI-H tumors. Therefore, our BRAF and MSI-H analyses
indicate that tumors may not belong to the serrated path-
way, which needs additional investigation. Most hyper-
plastic polyps occur in the rectum and sigmoid colon, but
most serrated (hyperplastic) polyps occur in the right
colon and are associated with proximal cancers [40,41].
All but one (13%) Omani, 79% Iranian, 66% of African
American MSI-H tumors were proximal with no evidence
of serrated hyperplastic polyps. Tumors in these popula-
tions were moderately differentiated with mixed adeno-
mas. Therefore, at this time it is not clear whether or not
mixed adenoma types have any role in the MSI-H in Afri-
can Americans.
The population of the Sultanate of Oman is especially
interesting because it represents a combination of African
and Asian heritage in a small country with the distribution
of CRC disease in young people, which may be due to the
age structure of the population in Oman. The effect of
environmental factors such as diet, physical activity,
access to health care, frequent tribal marriage and lifestyle
can not be ruled out for the occurrence of the CRC in
young age [9,10,42,43]. The Iranian population is a large
collection of ethnic groups and their descent were from
ancient Iranian peoples[44]. Modern Persians themselves
are also a heterogeneous group of peoples descended
from various Caucasian peoples [14,45]. The younger age
distribution of Iranian CRC disease also may be due to the
age structure of the population. However, the effect of
environmental factors such as diet and lifestyle can not be
ruled out. Our data on CRC lead us to speculate the com-
plex interactions of genotype, environmental factors
(such as diet), and other lifestyle factors in the pattern of
bowel cancer. Further epidemiology data to compare the
age-specific incident rates for Oman, Iran and African
American is needed to confirm this finding.
The proximal location of tumors in African Americans is
consistent with the tumors in Western and Asian studies
[31-33,46,47] which may reflect the impact of western
diets on the African Americans. However, the high MSI
level for African Americans for this limited sample size
may in part be due to the increased age of these patients
along with finding the majority of the tumors on the right
side of the colon. The Iranian tumors closely mimic what
we see in Caucasians in the U.S., most tumors are left
sided, most of the MSI-H tumors are right sided and the
MSI-H tumors are associated with higher tumor differen-
tiation. The distal location of the Omani tumors and the
low MSI level is an important observation compared to
the moderate and high proximal MSI level in Iranian and
African American tumors, respectively. The alteration of
K-RAS may also contribute to the methylator phenotype
in CRC, especially in the Iranian tumors, which we plan to
study in the future [30]. The rate of mutation and its level
in MMR deficiency may contribute and determine the
frameshift rate for the loss of these proteins in CRC, hence
different behavior from these tumors.
All of these factors may contribute to the risk of colon can-
cer and presentation of the disease in African American,
Omani and Iranian patients. We cannot rule out a genetic
predisposition in these patients since we did not have
access to detailed family history and, therefore, some of
the subjects may have had genetic and epigenetic predis-
positions. In this study we did not use other groups suchMolecular Cancer 2008, 7:68 http://www.molecular-cancer.com/content/7/1/68
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as white Americans, other Africans and Asian in our con-
trols for any direct or indirect comparison analysis. We
plan to have a more detailed study regarding the diversity
of these populations since the scope of this study focused
on the clinicopathological features.
In conclusion, this first comparative clinicopathological
investigation in three different populations suggests that
the MSI-H CRC phenotype in African American, Iranian
and Omani patients is significantly associated with BRAF
mutation and hMLH1 expression. CRCs in African Amer-
icans tend to be higher in microsatellite instability (32%)
and more often located in the proximal colon, compared
to Iranian and Omani CRC tumors. The high level of MSI-
H in African Americans may have significant implications
in treatment plans, because MSI-H lesions are often right-
sided and may show a different response to chemothera-
peutic agents such as 5-fluorourcil [48].
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